

Miroslav Odinak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5896177/publications.pdf>

Version: 2024-02-01

23
papers

1,095
citations

1307594

7
h-index

752698

20
g-index

32
all docs

32
docs citations

32
times ranked

1640
citing authors

#	ARTICLE	IF	CITATIONS
1	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <i>Lancet</i> , The, 2018, 391, 1263-1273.	13.7	684
2	Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. <i>Annals of Neurology</i> , 2008, 63, 611-620.	5.3	171
3	Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open) <i>Tj ETQq1</i> 1.0, 784314, 119	0.4	119
4	Use of Memantine (akatinol) for the Correction of Cognitive Impairments in Parkinsonâ€™s Disease Complicated by Dementia. <i>Neuroscience and Behavioral Physiology</i> , 2010, 40, 149-155.	0.4	47
5	Treatment of Exacerbations of Multiple Sclerosis without the Use of Corticosteroids: The Role of Metabolic and Antioxidant Therapy. <i>Neuroscience and Behavioral Physiology</i> , 2012, 42, 123-127.	0.4	9
6	A Comparative Placebo-Controlled Clinical Trial of the Efficacy and Safety of Glatiramer Acetate 20 mg in Patients with Remitting Multiple Sclerosis: First-Year Study Results. <i>Neuroscience and Behavioral Physiology</i> , 2018, 48, 351-357.	0.4	6
7	Thalamic nuclei degeneration in multiple sclerosis. <i>Journal of Clinical Neuroscience</i> , 2021, 89, 375-380.	1.5	6
8	Transplantation of Mesenchymal Stem Cells in Multiple Sclerosis. <i>Neuroscience and Behavioral Physiology</i> , 2012, 42, 516-520.	0.4	4
9	Opportunities in multimodal neuroimaging for optimizing thrombolytic therapy for ischemic stroke. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2016, 8, 9-15.	1.2	4
10	Susceptibility-weighted MR imaging (SWI) of basal ganglia iron deposition in the early and advanced stages of Parkinson's disease. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2019, 11, 30-36.	1.2	4
11	Potential of Preventive Treatment of Alzheimerâ€™s Disease: Results of a Three-Year Prospective Open Comparative Trial of the Efficacy and Safety of Courses of Treatment with Cerebrolysin and Cavinton in Elderly Patients with Mild Cognitive Impairment Syndrome. <i>Neuroscience and Behavioral Physiology</i> , 2011, 41, 391-398.	0.4	2
12	The algorithm of reperfusion treatment of the ischemic stroke: focus on DAWN and DEFUSE-3 trials. <i>Arterial Hypertension (Russian Federation)</i> , 2021, 27, 29-40.	0.4	1
13	Signs and Symptoms of Central Nervous System Involvement and Their Pathogenesis in COVID-19 According to The Clinical Data (Review). <i>Obshchaya Reanimatologiya</i> , 2021, 17, 65-77.	1.0	1
14	The Effect of Iron Accumulation in the Basal Ganglia on the Dysfunction of the Extrapyramidal System in Parkinsonâ€™s Disease. <i>Russian Neurological Journal</i> , 2020, 25, 29-37.	0.3	1
15	Changes in retinal structures as markers of multiple sclerosis progression. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2021, 13, 55-61.	1.2	1
16	Perfluorodecalin-induced changes in clinical and immunological parameters of experimental allergic encephalomyelitis. <i>Bulletin of Experimental Biology and Medicine</i> , 1997, 123, 273-275.	0.8	0
17	The Ergotropic Activity Index as an Integral Indicator of the Suprasegmental Autonomic Activity. <i>Human Physiology</i> , 2003, 29, 318-323.	0.4	0
18	Correction of Subdementia Cognitive Impairments in Patients with Cerebral Ischemia. <i>Neuroscience and Behavioral Physiology</i> , 2014, 44, 927-932.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Use of Succinates for Correction of Metabolic Impairments in the Ischemic Penumbra Zone in Stroke Patients. <i>Neuroscience and Behavioral Physiology</i> , 2015, 45, 600-604.	0.4	0
20	Cortical cerebral atrophy in patients with Parkinsonâ€™s disease: New opportunities for in vivo diagnostics. <i>Human Physiology</i> , 2016, 42, 905-909.	0.4	0
21	A.A. Mikhailenko, M.M. Odinak, N.N. Yakhno Â«The history of Russian neurology, The Moscow neurological schoolÂ». St. Petersburg. 2015;511. <i>Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova</i> , 2016, 116, 130.	0.7	0
22	Mozart effect in patients with epilepsy. <i>Epilepsy and Paroxysmal Conditions</i> , 2021, 13, 264-273.	0.5	0
23	Clinical-Morphological Risk Factors for the Development of Epilepsy in Patients with Glial and Metastatic Brain Tumors. <i>Neuroscience and Behavioral Physiology</i> , 0, , .	0.4	0